Home  >  Diseases > Lorcaserin HCL (Belviq)

Lorcaserin HCL (Belviq)

Lorcaserin HCL (Belviq)

Belviq is a general prescription of medicine that is normally used to treat the symptoms or the signs of Obesity. Belviq may be used alone or with another form of medication.

Belviq basically depends or belongs to a class of drugs which is called CNS Stimulants, Anorexiants; Serotonin 5-HT2C-Receptor Agonists.

It is researched over the usage of this dose for children, while this is not known if Belviq is safe and effective in children.

What are the possible side effects of Belviq?

Belviq may cause serious side effects which also includes:

  • Unusual changes in mood or behaviour,
  • Thoughts of hurting yourself,
  • Dry eyes,
  • Blurred vision,
  • Feelings of standing next to yourself,
  • Memory problems,
  • Trouble concentrating,

Limitations Of Use

Most importantly the measure of safety and efficacy of coadministration of BELVIQ with other products intended for weight loss while by including some prescription drugs (e.g., phentermine), over-the-counter drugs and herbal preparations have not been established.

The effect of BELVIQ on cardiovascular morbidity and mortality has not been established.


Dosage and Administration

The recommended actual dose of BELVIQ is normally 10 mg, which is administered orally at least twice daily. Do not exceed recommended dose.

BELVIQ can be normally taken with or without food as well.

Response to therapy or treatment is must be evaluated over by a week of 12. While if a patient has not lost at least 5% of baseline body weight, can discontinue the having of BELVIQ, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with perfect and continued treatment.

Dosage Forms and Strengths

BELVIQ is normally offered or provided as with packed of blue, film-coated, 10 mg tablets. The tablets are round, biconvex, debossed with “A” on one side and “10” on the other side.

Most Common Adverse Reactions

Because the clinical trials are far conducted under the widely varying conditions, like as adverse reaction rates, are normally observed in the clinical trials of a drug that can't be directly in a while compared to the rates of others in the clinical trials of another drug and which may not reflect the similar rates which was observed in the practice.

The much common adverse reactions for non-diabetic patients (greater than 7% and more commonly than the placebo) which was treated with BELVIQ which was compared to placebo were headache, dizziness, fatigue, nausea, dry mouth, and constipation. The most common adverse reactions for diabetic patients were hypoglycaemia, headache, back pain, cough, and fatigue. 


Leave a Comment